This company has been marked as potentially delisted and may not be actively trading. Alterity Therapeutics (PRAN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock PRAN vs. EPRX, PROC, ENTA, IRWD, TNXP, SLS, NLTX, CTNM, BHST, and XBITShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Eupraxia Pharmaceuticals (EPRX), Procaps Group (PROC), Enanta Pharmaceuticals (ENTA), Ironwood Pharmaceuticals (IRWD), Tonix Pharmaceuticals (TNXP), SELLAS Life Sciences Group (SLS), Neoleukin Therapeutics (NLTX), Contineum Therapeutics (CTNM), BioHarvest Sciences (BHST), and XBiotech (XBIT). These companies are all part of the "medical" sector. Alterity Therapeutics vs. Eupraxia Pharmaceuticals Procaps Group Enanta Pharmaceuticals Ironwood Pharmaceuticals Tonix Pharmaceuticals SELLAS Life Sciences Group Neoleukin Therapeutics Contineum Therapeutics BioHarvest Sciences XBiotech Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Alterity Therapeutics (NASDAQ:PRAN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment. Do insiders and institutionals hold more shares of EPRX or PRAN? 3.6% of Alterity Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is EPRX or PRAN more profitable? Alterity Therapeutics' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -219.64% -96.00% Alterity Therapeutics N/A N/A N/A Does the MarketBeat Community prefer EPRX or PRAN? Alterity Therapeutics received 184 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 57.67% of users gave Alterity Therapeutics an outperform vote. CompanyUnderperformOutperformEupraxia PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo VotesAlterity TherapeuticsOutperform Votes18857.67% Underperform Votes13842.33% Which has better earnings & valuation, EPRX or PRAN? Alterity Therapeutics has higher revenue and earnings than Eupraxia Pharmaceuticals. Alterity Therapeutics is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$28.22M-$0.76-5.01Alterity Therapeutics$150K210.04-$6.40M-$0.70-5.06 Does the media prefer EPRX or PRAN? In the previous week, Eupraxia Pharmaceuticals had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for Eupraxia Pharmaceuticals and 1 mentions for Alterity Therapeutics. Eupraxia Pharmaceuticals' average media sentiment score of 0.89 beat Alterity Therapeutics' score of 0.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer EPRX or PRAN? Eupraxia Pharmaceuticals currently has a consensus target price of $10.50, suggesting a potential upside of 175.59%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Alterity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Alterity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAlterity Therapeutics beats Eupraxia Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAN vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.51M$6.68B$5.44B$7.81BDividend YieldN/A3.20%5.44%4.30%P/E Ratio-5.067.1422.1418.36Price / Sales210.04238.91389.71101.37Price / CashN/A65.6738.2034.62Price / Book2.536.266.664.18Net Income-$6.40M$142.48M$3.21B$247.71M Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRANAlterity TherapeuticsN/A$3.54+0.9%N/A+50.6%$31.51M$150,000.00-5.0614Gap DownEPRXEupraxia Pharmaceuticals2.5472 of 5 stars$3.10+2.3%$10.50+238.7%+31.8%$111.13MN/A-4.3129News CoverageGap UpPROCProcaps GroupN/A$0.95-40.3%N/A-65.5%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeENTAEnanta Pharmaceuticals3.9249 of 5 stars$4.93+5.1%$17.25+249.9%-56.1%$105.17M$66.59M-1.00160Positive NewsIRWDIronwood Pharmaceuticals4.5924 of 5 stars$0.65-31.5%$7.80+1,103.9%-89.2%$104.84M$351.41M-21.60220Gap UpHigh Trading VolumeTNXPTonix Pharmaceuticals1.8287 of 5 stars$16.15-4.3%$585.00+3,522.3%-96.6%$103.93M$10.09M0.0050SLSSELLAS Life Sciences Group0.205 of 5 stars$1.14+0.9%N/A-13.0%$103.57M$1M-1.6510News CoverageNLTXNeoleukin TherapeuticsN/A$11.00+22.6%N/A-50.5%$103.38MN/A-3.5490News CoverageHigh Trading VolumeCTNMContineum Therapeutics1.8082 of 5 stars$3.99-0.5%$24.80+521.6%-71.6%$103.23M$50M-0.8131BHSTBioHarvest SciencesN/A$5.90+5.2%$13.00+120.3%N/A$96.91M$25.19M-4.72N/AUpcoming EarningsNews CoverageHigh Trading VolumeXBITXBiotech0.7455 of 5 stars$3.12-4.9%N/A-63.3%$95.12M$4.01M-2.89100News CoveragePositive News Related Companies and Tools Related Companies Eupraxia Pharmaceuticals Competitors Procaps Group Competitors Enanta Pharmaceuticals Competitors Ironwood Pharmaceuticals Competitors Tonix Pharmaceuticals Competitors SELLAS Life Sciences Group Competitors Neoleukin Therapeutics Competitors Contineum Therapeutics Competitors BioHarvest Sciences Competitors XBiotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAN) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRAN Stock Free PRAN Stock Alerts